Q-omics provides the consensus-scored FLRT1 profile across patient tissues and cancer cell-line models. FLRT1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FLRT1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, FLRT1 RNA expression shows 19,220 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, KIRC, and TGCT as cancer lineages where FLRT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FLRT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FLRT1 survival associations across molecular data types. FLRT1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FLRT1 RNA expression–survival associations across cancer types. High FLRT1 expression shows unfavorable associations in LIHC, COAD and MESO, but favorable associations in UCS, LGG and ESCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for FLRT1 RNA expression.
This table summarizes FLRT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FLRT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FLRT1 shows lower tumor expression in KIRC, KIRP, THCA and KICH and higher tumor expression in LIHC and LUSC. The KIRC box plot shows higher FLRT1 RNA expression in normal versus tumor tissue (log2 FC = −2.272, t-test p < 0.001).
This table shows molecular features associated with FLRT1 in patient tissues and cancer cell lines. In patient samples, FLRT1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FLRT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
